Skip to main content
OpenTrials
Completed

NCT Number: NCT04256512

Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients

This clinical trial investigates the effect and tolerability of cryotherapy and to evaluate whether they can prevent or improve taxane-induced sensory peripheral neuropathy in breast cancer patients. Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. Patients receiving cryotherapy during infusion of taxane therapy may have lower incidence of peripheral neuropathy, better physical function, and higher quality of life as compared to patients previously reported in literature.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States

About this study

PRIMARY OBJECTIVE:

I. To investigate the efficacy and tolerability of cryotherapy (Elasto Gel frozen mittens and foot wraps) and to evaluate whether they can prevent or ameliorate taxane-induced sensory peripheral neuropathy.

OUTLINE:

Patients wear Elasto Gel Therapy Mittens and Foot Wraps on both hands and feet 15 minutes prior to each infusion, during the entire infusion, and for 15 minutes after the completion of each infusion during their three months of treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >= 18 years of age with a diagnosis of breast cancer
  • Patients receiving 12-18 weeks of chemotherapy with a taxane-based regimen (4 cycles of weekly x 3 paclitaxel or 4-6 cycles of docetaxel every 3 weeks)
  • Absence of sensory peripheral neuropathy, skin or nail disorders at the start of treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Ability to complete questionnaires by themselves or with assistance
  • Ability to give signed informed consent

Exclusion criteria

  • History of prior sensory/motor peripheral neuropathy from any cause
  • History of prior Raynaud's phenomenon
  • History of cryoglobulinemia
  • Active peripheral vascular disease
  • Cold intolerance
  • Prior exposure to neurotoxic chemotherapy in the last 10 years
  • Hand-foot syndrome
  • Tumor metastasis in bone, soft tissue, or skin of the hands or feet
  • Absence of one or more fingers or toes
  • Prior exposure to taxane chemotherapy

Treatment and study plan

Medical Device Usage and Evaluation

Device

Wear Elasto Gel Therapy Mittens and Foot Wraps

Questionnaire Administration

Other

Ancillary studies

Primary outcomes

  1. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN)

    Time frame: During chemotherapy (baseline), after chemotherapy (1 week post baseline), at 3 month follow up

    Number of subjects to experience chemotherapy induced peripheral neuropathy (CIPN).

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Cryotherapy to Prevent Taxane-Induced Sensory Neuropathy of the Hands and Feet

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Feb 5, 2020
Registry last updated
Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.